HRP20170185T1 - Nove 5-aminotetrahidrokinolin-2-karboksilne kiseline i njihova uporaba - Google Patents
Nove 5-aminotetrahidrokinolin-2-karboksilne kiseline i njihova uporaba Download PDFInfo
- Publication number
- HRP20170185T1 HRP20170185T1 HRP20170185TT HRP20170185T HRP20170185T1 HR P20170185 T1 HRP20170185 T1 HR P20170185T1 HR P20170185T T HRP20170185T T HR P20170185TT HR P20170185 T HRP20170185 T HR P20170185T HR P20170185 T1 HRP20170185 T1 HR P20170185T1
- Authority
- HR
- Croatia
- Prior art keywords
- formula
- compound
- solvates
- salts
- image
- Prior art date
Links
- YCTMSIGDGYEBRJ-UHFFFAOYSA-N 5-amino-1,2,3,4-tetrahydroquinoline-2-carboxylic acid Chemical class N1C(C(O)=O)CCC2=C1C=CC=C2N YCTMSIGDGYEBRJ-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 17
- 150000003839 salts Chemical group 0.000 claims 14
- 239000012453 solvate Chemical group 0.000 claims 14
- 229910052731 fluorine Chemical group 0.000 claims 11
- 239000011737 fluorine Chemical group 0.000 claims 11
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 10
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 9
- 229910052801 chlorine Inorganic materials 0.000 claims 9
- 239000000460 chlorine Chemical group 0.000 claims 9
- 239000001257 hydrogen Substances 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 8
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 5
- 125000001140 1,4-phenylene group Chemical group [H]C1=C([H])C([*:2])=C([H])C([H])=C1[*:1] 0.000 claims 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 4
- 229910052794 bromium Inorganic materials 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 claims 4
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 4
- 206010002383 Angina Pectoris Diseases 0.000 claims 3
- 206010003210 Arteriosclerosis Diseases 0.000 claims 3
- 206010019280 Heart failures Diseases 0.000 claims 3
- 206010020772 Hypertension Diseases 0.000 claims 3
- 208000001647 Renal Insufficiency Diseases 0.000 claims 3
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 230000003176 fibrotic effect Effects 0.000 claims 3
- 208000028867 ischemia Diseases 0.000 claims 3
- 230000004089 microcirculation Effects 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 208000002815 pulmonary hypertension Diseases 0.000 claims 3
- 230000009424 thromboembolic effect Effects 0.000 claims 3
- 208000019553 vascular disease Diseases 0.000 claims 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- -1 cyano, methyl Chemical group 0.000 claims 2
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims 2
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims 2
- 201000006370 kidney failure Diseases 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims 2
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 claims 2
- HFCWZVGKWGOBKV-UHFFFAOYSA-N 5-[2-(4-carboxyphenyl)ethyl-[2-[2-[[2-chloro-4-[4-(trifluoromethyl)phenyl]phenyl]methoxy]phenyl]ethyl]amino]-5,6,7,8-tetrahydroquinoline-2-carboxylic acid Chemical compound C1=CC(C(=O)O)=CC=C1CCN(C1C2=CC=C(N=C2CCC1)C(O)=O)CCC1=CC=CC=C1OCC1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)C=C1Cl HFCWZVGKWGOBKV-UHFFFAOYSA-N 0.000 claims 1
- XHLILZGNLWHVCB-UHFFFAOYSA-N 5-[4-carboxybutyl-[2-[2-[[2-chloro-4-[4-(trifluoromethyl)phenyl]phenyl]methoxy]phenyl]ethyl]amino]-5,6,7,8-tetrahydroquinoline-2-carboxylic acid Chemical compound C1CCC2=NC(C(O)=O)=CC=C2C1N(CCCCC(=O)O)CCC1=CC=CC=C1OCC(C(=C1)Cl)=CC=C1C1=CC=C(C(F)(F)F)C=C1 XHLILZGNLWHVCB-UHFFFAOYSA-N 0.000 claims 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- 102000010180 Endothelin receptor Human genes 0.000 claims 1
- 229940118365 Endothelin receptor antagonist Drugs 0.000 claims 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims 1
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 claims 1
- 108091006335 Prostaglandin I receptors Proteins 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 230000003055 anti-obstructive effect Effects 0.000 claims 1
- 230000002785 anti-thrombosis Effects 0.000 claims 1
- 229960004676 antithrombotic agent Drugs 0.000 claims 1
- 230000036772 blood pressure Effects 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 239000002308 endothelin receptor antagonist Substances 0.000 claims 1
- 125000004185 ester group Chemical group 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 239000003119 guanylate cyclase activator Substances 0.000 claims 1
- 230000007062 hydrolysis Effects 0.000 claims 1
- 238000006460 hydrolysis reaction Methods 0.000 claims 1
- 229940125721 immunosuppressive agent Drugs 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000004060 metabolic process Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 231100000252 nontoxic Toxicity 0.000 claims 1
- 230000003000 nontoxic effect Effects 0.000 claims 1
- 229940082615 organic nitrates used in cardiac disease Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 claims 1
- 150000003815 prostacyclins Chemical class 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12177284 | 2012-07-20 | ||
| EP13167967 | 2013-05-16 | ||
| EP13744464.2A EP2875003B1 (de) | 2012-07-20 | 2013-07-16 | Neue 5-aminotetrahydrochinolin-2-carbonsäuren und ihre verwendung |
| PCT/EP2013/065017 WO2014012934A1 (de) | 2012-07-20 | 2013-07-16 | Neue 5-aminotetrahydrochinolin-2-carbonsäuren und ihre verwendung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20170185T1 true HRP20170185T1 (hr) | 2017-03-24 |
Family
ID=48914233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20170185TT HRP20170185T1 (hr) | 2012-07-20 | 2017-02-02 | Nove 5-aminotetrahidrokinolin-2-karboksilne kiseline i njihova uporaba |
Country Status (41)
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1993360T3 (pl) | 2005-12-28 | 2017-08-31 | Vertex Pharmaceuticals Incorporated | Stałe postacie n-[2,4-bis(1,1-dimetyloetylo)-5-hydroksyfenylo]-1,4- dihydro-4-oksochinolino-3-karboksyamidu |
| DE102011007272A1 (de) | 2011-04-13 | 2012-10-18 | Bayer Pharma Aktiengesellschaft | Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung |
| EP2840076B1 (en) * | 2012-04-16 | 2017-10-25 | TOA Eiyo Ltd. | Bicyclic compound |
| HUE030540T2 (en) * | 2012-07-20 | 2017-05-29 | Bayer Pharma AG | New 5-aminotetrahydroquinoline-2-carboxylic acids and their use |
| EP2874993B1 (de) | 2012-07-20 | 2016-08-24 | Bayer Pharma Aktiengesellschaft | Substituierte aminoindan- und aminotetralin-carbonsäuren und ihre verwendung |
| FR3000065A1 (fr) | 2012-12-21 | 2014-06-27 | Univ Lille Ii Droit & Sante | Composes bicycliques ayant une activite potentialisatrice de l'activite d'un antibiotique actif contre les mycobacteries-composition et produit pharmaceutiques comprenant de tels composes |
| JP6746569B2 (ja) | 2014-10-07 | 2020-08-26 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | 嚢胞性線維症膜貫通コンダクタンス制御因子のモジュレーターの共結晶 |
| TN2017000465A1 (en) | 2015-05-06 | 2019-04-12 | Bayer Pharma AG | The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of digital ulcers (du) concomitant to systemic sclerosis (ssc) |
| WO2017013010A1 (de) | 2015-07-23 | 2017-01-26 | Bayer Pharma Aktiengesellschaft | Stimulatoren und/oder aktivatoren der löslichen guanylatzyklase (sgc) in kombination mit einem inhibitor der neutralen endopeptidase (nep inhibitor) und/oder einem angiotensin aii-antagonisten und ihre verwendung |
| EP3489219B1 (en) * | 2016-07-22 | 2020-12-16 | TOA Eiyo Ltd. | Therapeutic agent for glaucoma |
| CA3039735A1 (en) | 2016-10-11 | 2018-04-19 | Bayer Pharma Aktiengesellschaft | Combination containing sgc activators and mineralocorticoid receptor antagonists |
| WO2018153899A1 (de) | 2017-02-22 | 2018-08-30 | Bayer Pharma Aktiengesellschaft | Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit stimulatoren und/oder aktivatoren der löslichen guanylatcyclase (sgc) |
| JP2021500366A (ja) | 2017-10-24 | 2021-01-07 | バイエル・アクチエンゲゼルシヤフト | 置換されているイミダゾピリジンアミド類及びそれらの使用 |
| WO2019081456A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT |
| EP3498298A1 (en) | 2017-12-15 | 2019-06-19 | Bayer AG | The use of sgc stimulators and sgc activators alone or in combination with pde5 inhibitors for the treatment of bone disorders including osteogenesis imperfecta (oi) |
| CN108218770A (zh) * | 2018-02-28 | 2018-06-29 | 南京波普生物医药研发有限公司 | 2-氯-7,8-二氢-6h-喹啉-5-酮的制备方法 |
| CA3098475A1 (en) | 2018-04-30 | 2019-11-07 | Bayer Aktiengesellschaft | The use of sgc activators and sgc stimulators for the treatment of cognitive impairment |
| EA202092680A1 (ru) | 2018-05-15 | 2021-04-13 | Байер Акциенгезельшафт | 1,3-тиазол-2-ил-замещенные бензамиды для лечения заболеваний, ассоциированных с сенситизацией нервных волокон |
| EP3574905A1 (en) | 2018-05-30 | 2019-12-04 | Adverio Pharma GmbH | Method of identifying a subgroup of patients suffering from dcssc which benefits from a treatment with sgc stimulators and sgc activators in a higher degree than a control group |
| US10905667B2 (en) | 2018-07-24 | 2021-02-02 | Bayer Pharma Aktiengesellschaft | Orally administrable modified-release pharmaceutical dosage form |
| EP3911675A1 (en) | 2019-01-17 | 2021-11-24 | Bayer Aktiengesellschaft | Methods to determine whether a subject is suitable of being treated with an agonist of soluble guanylyl cyclase (sgc) |
| WO2020164008A1 (en) | 2019-02-13 | 2020-08-20 | Bayer Aktiengesellschaft | Process for the preparation of porous microparticles |
| WO2020216669A1 (de) | 2019-04-23 | 2020-10-29 | Bayer Aktiengesellschaft | Phenylsubstituierte imidazopyridinamide und ihre verwendung |
| SG11202111587VA (en) | 2019-05-07 | 2021-11-29 | Bayer Ag | Masp inhibitory compounds and uses thereof |
| EP3822265A1 (en) | 2019-11-15 | 2021-05-19 | Bayer AG | Substituted hydantoinamides as adamts7 antagonists |
| EP3822268A1 (en) | 2019-11-15 | 2021-05-19 | Bayer Aktiengesellschaft | Substituted hydantoinamides as adamts7 antagonists |
| MX2022014655A (es) | 2020-05-20 | 2022-12-15 | Bayer Ag | Proceso para preparar (5s)-5-({2-[4-(butoxicarbonil)fenil]etil}[2- (2-{[3-cloro-4'-(trifluorometil)[bifenil]-4-il]metoxi}fenil)etil] amino)-5,6,7,8-tetrahidroquinolin-2-carboxilato de butilo. |
| AR128147A1 (es) | 2021-12-29 | 2024-03-27 | Bayer Ag | Procedimiento para la preparación del ácido (5s)-[2-(4-carboxifenil)etil][2-(2-[3-cloro-4-(trifluorometil)bifenil-4-il]metoxifenil)etil]amino-5,6,7,8-tetrahidroquinolina-2-carboxílico y sus formas cristalinas para su uso como compuesto farmacéuticamente activo |
| AR128145A1 (es) | 2021-12-29 | 2024-03-27 | Bayer Ag | Formulación farmacéutica de polvo seco para inhalación y proceso de preparación |
| TW202342034A (zh) | 2021-12-29 | 2023-11-01 | 德商拜耳廠股份有限公司 | 心肺病症之治療 |
| WO2023237577A1 (en) | 2022-06-09 | 2023-12-14 | Bayer Aktiengesellschaft | Soluble guanylate cyclase activators for use in the treatment of heart failure with preserved ejection fraction in women |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8004002L (sv) | 1980-05-29 | 1981-11-30 | Arvidsson Folke Lars Erik | Terapeutiskt anvendbara tetralinderivat |
| IL65501A (en) | 1981-05-08 | 1986-04-29 | Astra Laekemedel Ab | 1-alkyl-2-aminotetralin derivatives,process for their preparation and pharmaceutical compositions containing them |
| DE3718317A1 (de) | 1986-12-10 | 1988-06-16 | Bayer Ag | Substituierte basische 2-aminotetraline |
| DE3719924A1 (de) | 1986-12-22 | 1988-06-30 | Bayer Ag | 8-substituierte 2-aminotetraline |
| JP2785879B2 (ja) | 1989-05-31 | 1998-08-13 | ジ・アップジョン・カンパニー | 治療学的に有用な２―アミノテトラリン誘導体 |
| FR2659853A1 (fr) | 1990-03-22 | 1991-09-27 | Midy Spa | Utilisation de derives 2-aminotetraliniques pour la preparation de medicaments destines a combattre les troubles de la motricite intestinale. |
| CA2180841C (en) | 1994-01-10 | 2007-03-27 | Sasson Cohen | 1-aminoindan derivatives and compositions thereof |
| DK1083889T3 (da) | 1998-06-01 | 2004-04-13 | Ortho Mcneil Pharm Inc | Tetrahydronaphthalenforbindelser og deres anvendelse til behandling af neurodegenerative sygdomme |
| DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
| DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
| GB9827467D0 (en) | 1998-12-15 | 1999-02-10 | Zeneca Ltd | Chemical compounds |
| DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| AR031176A1 (es) | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
| DE10109858A1 (de) | 2001-03-01 | 2002-09-05 | Bayer Ag | Neuartige halogensubstituierte Aminodicarbonsäurederivate |
| DE10109859A1 (de) | 2001-03-01 | 2002-09-05 | Bayer Ag | Neuartige Aminodicarbonsäurederivate |
| DE10109861A1 (de) * | 2001-03-01 | 2002-09-05 | Bayer Ag | Neuartige seitenkettenhalogenierte Aminodicarbonsäurederivate |
| DE10110750A1 (de) * | 2001-03-07 | 2002-09-12 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE10110749A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte Aminodicarbonsäurederivate |
| DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
| US20050032873A1 (en) | 2003-07-30 | 2005-02-10 | Wyeth | 3-Amino chroman and 2-amino tetralin derivatives |
| GB0318094D0 (en) * | 2003-08-01 | 2003-09-03 | Pfizer Ltd | Novel combination |
| US7803951B2 (en) | 2005-03-30 | 2010-09-28 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
| DE102005047946A1 (de) * | 2005-10-06 | 2007-05-03 | Bayer Healthcare Ag | Verwendung von Aktivatoren der löslichen Guanylatzyklase zur Behandlung von akuten und chronischen Lungenkrankheiten |
| DE102005050377A1 (de) | 2005-10-21 | 2007-04-26 | Bayer Healthcare Ag | Heterocyclische Verbindungen und ihre Verwendung |
| DE102006031175A1 (de) * | 2006-07-06 | 2008-01-10 | Bayer Healthcare Ag | Wässrige Arzneimittelformulierung von 4-[((4-Carboxybutyl)-(2[(4-phenethyl-benzyl)oxy]-phenethyl)amino)methyl]benzoesäur |
| WO2009023669A1 (en) | 2007-08-13 | 2009-02-19 | Janssen Pharmaceutica N.V. | Substituted 5,6,7,8-tetrahydroquinoline derivatives, compositions, and methods of use thereof |
| JP5298129B2 (ja) | 2007-09-06 | 2013-09-25 | メルク・シャープ・アンド・ドーム・コーポレーション | 可溶性グアニレートシクラーゼ活性化因子 |
| WO2010021882A2 (en) * | 2008-08-19 | 2010-02-25 | Janssen Pharmaceutica Nv | Cold menthol receptor antagonists |
| DE102010020553A1 (de) | 2010-05-14 | 2011-11-17 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 8-Alkoxy-2-aminotetralin-Derivate und ihre Verwendung |
| DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
| WO2011161099A1 (de) | 2010-06-25 | 2011-12-29 | Bayer Pharma Aktiengesellschaft | Verwendung von stimulatoren und aktivatoren der löslichen guanylatzyklase zur behandlung von sichelzellanämie und konservierung von blutersatzstoffen |
| AU2011275825A1 (en) | 2010-07-09 | 2013-02-07 | Bayer Intellectual Property Gmbh | Ring-fused pyrimidines and triazines and use thereof for the treatment and/or prophylaxis of cardiovascular diseases |
| DE102010040233A1 (de) | 2010-09-03 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Bicyclische Aza-Heterocyclen und ihre Verwendung |
| DE102010043379A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung |
| EP2683710B1 (en) | 2011-03-10 | 2017-07-19 | Boehringer Ingelheim International GmbH | Soluble guanylate cyclase activators |
| EP2840076B1 (en) * | 2012-04-16 | 2017-10-25 | TOA Eiyo Ltd. | Bicyclic compound |
| EP2874993B1 (de) | 2012-07-20 | 2016-08-24 | Bayer Pharma Aktiengesellschaft | Substituierte aminoindan- und aminotetralin-carbonsäuren und ihre verwendung |
| HUE030540T2 (en) * | 2012-07-20 | 2017-05-29 | Bayer Pharma AG | New 5-aminotetrahydroquinoline-2-carboxylic acids and their use |
-
2013
- 2013-07-16 HU HUE13744464A patent/HUE030540T2/en unknown
- 2013-07-16 PT PT137444642T patent/PT2875003T/pt unknown
- 2013-07-16 JP JP2015522074A patent/JP6251259B2/ja active Active
- 2013-07-16 LT LTEP13744464.2T patent/LT2875003T/lt unknown
- 2013-07-16 CN CN201380048579.2A patent/CN104822661B/zh active Active
- 2013-07-16 PL PL13744464T patent/PL2875003T3/pl unknown
- 2013-07-16 RS RS20170110A patent/RS55651B1/sr unknown
- 2013-07-16 EA EA201590251A patent/EA028918B9/ru not_active IP Right Cessation
- 2013-07-16 MY MYPI2015000125A patent/MY172994A/en unknown
- 2013-07-16 PE PE2015000049A patent/PE20150350A1/es active IP Right Grant
- 2013-07-16 SG SG11201408421TA patent/SG11201408421TA/en unknown
- 2013-07-16 SI SI201330514A patent/SI2875003T1/sl unknown
- 2013-07-16 EP EP13744464.2A patent/EP2875003B1/de active Active
- 2013-07-16 DK DK13744464.2T patent/DK2875003T3/en active
- 2013-07-16 NZ NZ702977A patent/NZ702977A/en unknown
- 2013-07-16 ES ES13744464.2T patent/ES2616036T3/es active Active
- 2013-07-16 BR BR112015001211-6A patent/BR112015001211B1/pt active IP Right Grant
- 2013-07-16 CA CA2879369A patent/CA2879369C/en active Active
- 2013-07-16 WO PCT/EP2013/065017 patent/WO2014012934A1/de active Application Filing
- 2013-07-16 MX MX2015000739A patent/MX360863B/es active IP Right Grant
- 2013-07-16 ME MEP-2017-30A patent/ME02603B/me unknown
- 2013-07-16 KR KR1020157001058A patent/KR102137517B1/ko active IP Right Grant
- 2013-07-16 AU AU2013292046A patent/AU2013292046C1/en active Active
- 2013-07-16 SG SG10201700454PA patent/SG10201700454PA/en unknown
- 2013-07-18 JO JOP/2013/0216A patent/JO3343B1/ar active
- 2013-07-18 US US13/945,675 patent/US8981104B2/en active Active
- 2013-07-18 AR ARP130102566A patent/AR091838A1/es active IP Right Grant
- 2013-07-19 TW TW102125865A patent/TWI598338B/zh active
- 2013-07-19 UY UY0001034918A patent/UY34918A/es active IP Right Grant
-
2014
- 2014-12-19 ZA ZA2014/09394A patent/ZA201409394B/en unknown
-
2015
- 2015-01-11 IL IL236616A patent/IL236616B/en active IP Right Grant
- 2015-01-14 PH PH12015500106A patent/PH12015500106A1/en unknown
- 2015-01-15 CO CO15007422A patent/CO7240369A2/es unknown
- 2015-01-16 CL CL2015000120A patent/CL2015000120A1/es unknown
- 2015-01-16 DO DO2015000012A patent/DOP2015000012A/es unknown
- 2015-01-19 EC ECIEPI20151882A patent/ECSP15001882A/es unknown
- 2015-01-19 TN TNP2015000026A patent/TN2015000026A1/fr unknown
- 2015-01-20 GT GT201500011A patent/GT201500011A/es unknown
- 2015-01-20 CR CR20150020A patent/CR20150020A/es unknown
- 2015-01-29 US US14/609,122 patent/US9688636B2/en active Active
- 2015-10-13 HK HK15109955.7A patent/HK1209413A1/xx unknown
-
2017
- 2017-02-02 HR HRP20170185TT patent/HRP20170185T1/hr unknown
- 2017-02-03 CY CY20171100161T patent/CY1118588T1/el unknown
- 2017-05-19 US US15/600,132 patent/US10053428B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20170185T1 (hr) | Nove 5-aminotetrahidrokinolin-2-karboksilne kiseline i njihova uporaba | |
| RU2012121577A (ru) | Замещенные 3-фенилпропионовые кислоты и их применение | |
| HRP20150702T1 (hr) | Supstituirani 4-aril-1,4-dihidro-1,6-naftiridinamidi i njihova uporaba | |
| HRP20150341T1 (hr) | Heterocikliäśki supstituirani spojevi arila kao inhibitori hif | |
| RS53268B (en) | INDOLE DERIVATIVES AS AN ANTAGONISTS OF CRTH2 RECEPTORS | |
| JPWO2002092068A1 (ja) | カルボン酸誘導体化合物およびそれらを有効成分とする薬剤 | |
| ES2684334T3 (es) | Compuesto de amida | |
| RU2011123672A (ru) | Гетероароматические соединения для применения в качестве hif ингибиторов | |
| JP6688437B1 (ja) | ブチルフタリド−テルミサルタン混成物、その調製方法及びその応用 | |
| SI2956464T1 (en) | Substituted bisphenyl butanoic phosphonic acid derivatives as NEP inhibitors (neutral endopeptidases) | |
| BRPI0615158A2 (pt) | composto de 3-aminocarbazol, composição farmacêutica, uso de um composto de 3-aminocarbazol, e, método para preparar um composto | |
| RU2007132438A (ru) | Циклопропил-(2,3-диметилбензил)амид 7-{4-[2-(2,6-дихлор-4-метилфенокси)этокси]фенил}-3,9-диазабицикло[3.3.1]нон-6-ен-6-карбоновой кислоты в качестве ингибиторов ренина для лечения артериальной гипертензии | |
| SK10694A3 (en) | Compounds having angiotensine ii antagonistic activity | |
| RS53081B (en) | THIAZOLOPYRIDIN-2-ILOXY-PHENYL I AMINI THIAZOLOPYRIDIN-2-ILOXY-PHENYL KAO MODULATOR LEUKOTRIEN A4 HYDROLAZE | |
| US20040002493A1 (en) | Benzoic acid derivatives and pharmaceutical agents comprising the same as active ingredient | |
| EA039482B1 (ru) | Соединения-ингибиторы рецептора лизофосфатидной кислоты 1 (lpar1) | |
| RU2005137155A (ru) | Производные 9-азабицикло [3.3.1] нон-6-ена с гетероатомом на позиции 3 как ингибиторы ренина | |
| JP2021042207A (ja) | トロンボキサン受容体アンタゴニスト | |
| RU2007109601A (ru) | Антагонисты vla-4 | |
| RU2015105603A (ru) | Антагонисты минералокортикоидных рецепторов | |
| PT594019E (pt) | Bifenilos trissubstituidos como antagonistas da angiotensina ii | |
| RU2005137184A (ru) | Новые производные тропана | |
| WO2002045750A1 (fr) | Medicaments combines | |
| WO2004000813A1 (ja) | フェノキシピリジン誘導体又はその塩 | |
| JP2016539993A (ja) | Ｎ−置換ピラゾリルグアニジンｆ１ｆ０−ａｔｐアーゼ阻害剤及びその治療用途 |